Dynamic quotes: Off
|
ETFs with AMGN as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 8.26% | iShares NASDAQ Biotechnology Index Fund (IBB) | +41.92 (30.41%) |
| 5.87% | First Trust Amex Biotechnology Index Fund (FBT) | +13.32 (28.90%) |
| 5.74% | PowerShares Dynamic Biotech &Genome (PBE) | +6.58 (28.77%) |
| 5.71% | PowerShares Dynamic Pharmaceuticals (PJP) | +8.00 (23.00%) |
| 4.38% | Select Sector SPDR Fund - Health Care (XLV) | +8.71 (21.75%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. Our medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. We operate in one business segment: human therapeutics. We were incorporated in 1980 and organized as a Delaware corporation in 1987. Our public website is www.amgen.com. On our website, investors can find press releases, financial filings and other information about the Company. The U.S. Securities and Exchange Commission (SEC) website, www.sec.gov, also offers access to reports and documents we have electronically filed with or furnished to the SEC. ... More ...
Analyst Info |
|
| Annual EPS Est: | $6.45 |
| Quarterly EPS Est: | 1.68 |
| PEG Ratio: | 1.60 |
|
Mean Recommendation: View Summary / View All |
2.13 |
Data is provided by Zacks Investment Research

